Angelo Alonzo1, Joanna Fong2, Nicola Ball2, Donel Martin2, Nicholas Chand2, Colleen Loo3. 1. School of Psychiatry, University of New South Wales/Black Dog Institute, Hospital Road, Randwick, NSW 2031, Australia. Electronic address: a.alonzo@unsw.edu.au. 2. School of Psychiatry, University of New South Wales/Black Dog Institute, Hospital Road, Randwick, NSW 2031, Australia. 3. School of Psychiatry, University of New South Wales/Black Dog Institute, Hospital Road, Randwick, NSW 2031, Australia; St George Hospital, South Eastern Sydney Health, Level 2, James Laws House, Gray St, Kogarah, NSW 2217, Australia.
Abstract
BACKGROUND:Transcranial Direct Current Stimulation (tDCS) is a non-invasive, neuromodulation approach with promising efficacy for treating depression. To date, tDCS has been limited to clinical or research centre settings with treatment administered by staff. The aim of this study is to examine the efficacy, tolerability and feasibility of home-administered, remotely-supervised tDCS for depression. METHODS: In an open label trial, 34 participants used a Soterix 1 × 1 mini-CT device to self-administer 20-28 tDCS sessions (2 mA, 30 min, F3-anode and F8-cathode montage according to 10-20 EEG placement) over 4 weeks followed by a taper phase of 4 sessions 1 week apart. Participants were initially monitored via video link and then through completion of an online treatment diary. Mixed effects repeated measures analyses assessed change in mood scores. RESULTS: Mood improved significantly from baseline (27.47 on Montgomery-Asberg Depression Rating Scale) to 1 month after the end of acute treatment (15.48) (p < 0.001). Side effects were largely transient and minor. Outcomes were comparable to those reported in clinic-based trials. Protocol adherence was excellent with a drop-out rate of 6% and 93% of scheduled sessions completed. LIMITATIONS: The tDCS and remote monitoring procedures employed in this study require a level of manual dexterity and computer literacy, which may be challenging for some patients. This study did not have a control condition. CONCLUSIONS: This study provides initial evidence that home-based, remotely-supervised tDCS treatment may be efficacious and feasible for depressed patients and has high translational potential.
RCT Entities:
BACKGROUND: Transcranial Direct Current Stimulation (tDCS) is a non-invasive, neuromodulation approach with promising efficacy for treating depression. To date, tDCS has been limited to clinical or research centre settings with treatment administered by staff. The aim of this study is to examine the efficacy, tolerability and feasibility of home-administered, remotely-supervised tDCS for depression. METHODS: In an open label trial, 34 participants used a Soterix 1 × 1 mini-CT device to self-administer 20-28 tDCS sessions (2 mA, 30 min, F3-anode and F8-cathode montage according to 10-20 EEG placement) over 4 weeks followed by a taper phase of 4 sessions 1 week apart. Participants were initially monitored via video link and then through completion of an online treatment diary. Mixed effects repeated measures analyses assessed change in mood scores. RESULTS: Mood improved significantly from baseline (27.47 on Montgomery-Asberg Depression Rating Scale) to 1 month after the end of acute treatment (15.48) (p < 0.001). Side effects were largely transient and minor. Outcomes were comparable to those reported in clinic-based trials. Protocol adherence was excellent with a drop-out rate of 6% and 93% of scheduled sessions completed. LIMITATIONS: The tDCS and remote monitoring procedures employed in this study require a level of manual dexterity and computer literacy, which may be challenging for some patients. This study did not have a control condition. CONCLUSIONS: This study provides initial evidence that home-based, remotely-supervised tDCS treatment may be efficacious and feasible for depressedpatients and has high translational potential.
Authors: Hyein Cho; Lais B Razza; Lucas Borrione; Marom Bikson; Leigh Charvet; Tracy A Dennis-Tiwary; Andre R Brunoni; Pedro Sudbrack-Oliveira Journal: Focus (Am Psychiatr Publ) Date: 2022-01-25
Authors: Jasmina Paneva; Inge Leunissen; Teresa Schuhmann; Tom A de Graaf; Morten Gørtz Jønsson; Balder Onarheim; Alexander T Sack Journal: Front Hum Neurosci Date: 2022-06-09 Impact factor: 3.473
Authors: Marom Bikson; Colleen A Hanlon; Adam J Woods; Bernadette T Gillick; Leigh Charvet; Claus Lamm; Graziella Madeo; Adrienn Holczer; Jorge Almeida; Andrea Antal; Mohammad Reza Ay; Chris Baeken; Daniel M Blumberger; Salvatore Campanella; Joan A Camprodon; Lasse Christiansen; Colleen Loo; Jennifer T Crinion; Paul Fitzgerald; Luigi Gallimberti; Peyman Ghobadi-Azbari; Iman Ghodratitoostani; Roland H Grabner; Gesa Hartwigsen; Akimasa Hirata; Adam Kirton; Helena Knotkova; Evgeny Krupitsky; Paola Marangolo; Ester M Nakamura-Palacios; Weronika Potok; Samir K Praharaj; Christian C Ruff; Gottfried Schlaug; Hartwig R Siebner; Charlotte J Stagg; Axel Thielscher; Nicole Wenderoth; Ti-Fei Yuan; Xiaochu Zhang; Hamed Ekhtiari Journal: Brain Stimul Date: 2020-05-12 Impact factor: 8.955
Authors: Abrahão Fontes Baptista; Adriana Baltar; Alexandre Hideki Okano; Alexandre Moreira; Ana Carolina Pinheiro Campos; Ana Mércia Fernandes; André Russowsky Brunoni; Bashar W Badran; Clarice Tanaka; Daniel Ciampi de Andrade; Daniel Gomes da Silva Machado; Edgard Morya; Eduardo Trujillo; Jaiti K Swami; Joan A Camprodon; Katia Monte-Silva; Katia Nunes Sá; Isadora Nunes; Juliana Barbosa Goulardins; Marom Bikson; Pedro Sudbrack-Oliveira; Priscila de Carvalho; Rafael Jardim Duarte-Moreira; Rosana Lima Pagano; Samuel Katsuyuki Shinjo; Yossi Zana Journal: Front Neurol Date: 2020-11-25 Impact factor: 4.003
Authors: Lucas Borrione; Helena Bellini; Lais Boralli Razza; Ana G Avila; Chris Baeken; Anna-Katharine Brem; Geraldo Busatto; Andre F Carvalho; Adam Chekroud; Zafiris J Daskalakis; Zhi-De Deng; Jonathan Downar; Wagner Gattaz; Colleen Loo; Paulo A Lotufo; Maria da Graça M Martin; Shawn M McClintock; Jacinta O'Shea; Frank Padberg; Ives C Passos; Giovanni A Salum; Marie-Anne Vanderhasselt; Renerio Fraguas; Isabela Benseñor; Leandro Valiengo; Andre R Brunoni Journal: Braz J Psychiatry Date: 2020-03-16 Impact factor: 2.697